Loading organizations...
§ Private Profile · Milpitas, CA, USA
Biotechnology CDMO providing genome engineering products, custom iPSC services, and GMP-compliant cell lines for cell and gene therapies.
Based in Milpitas, California, Applied StemCell is a biotechnology contract research organization and CDMO that provides genome engineering products and custom stem cell services. The company utilizes CRISPR and its proprietary TARGATT knock-in technology to engineer modified cell lines and transgenic animal models for biomedical research and drug discovery. Operating with an estimated workforce of 50 to 200 employees, the firm generates revenue through B2B service fees, contract research, and the sale of standard laboratory reagents. The organization specifically focuses on expanding its Good Manufacturing Practice induced pluripotent stem cell capabilities to support allogeneic cell therapies. Following the 2020 spinoff of its clinical gene therapy division into the independent company ASC Therapeutics, the core business was acquired by private equity firm QHP Capital. Applied StemCell was founded in 2008 by Ruhong Jiang and Ruby Tsai.
Applied StemCell has raised $19.0M across 1 funding round.
Applied StemCell has raised $19.0M in total across 1 funding round.
Applied StemCell has raised $19.0M in total across 1 funding round.
Applied StemCell's investors include Jerry Xiao, BioSciKin, Jiang Zhang, VI Ventures.
Applied StemCell has raised $19.0M across 1 funding round. Most recently, it raised $19.0M Series D in June 2016.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 6, 2016 | $19M Series D | Jerry Xiao | Bioscikin, Jiang Zhang, VI Ventures | Announced |